NeuroVive Pharmaceutical AB is a leader in mitochondrial medicine, with one project in clinical phase II development for the prevention of moderate to severe traumatic brain injury NeuroSTAT and one project in clinical phase I KL . The R amp D portfolio consists of several late stage research programs in areas ranging from genetic mitochondrial disorders to cancer and metabolic diseases such as NASH. The company s strategy is to advance drugs for rare diseases through clinical development and into the market. The strategy for projects within larger indications outside the core focus area is out licensing in the preclinical phase. NeuroVive is listed on Nasdaq Stockholm, Sweden ticker: NVP . The share is also traded on the OTCQX Best Market in the US OTC: NEVPF .
Quote | Neurovive Pharm Ab Ord (OTCMKTS:NEVPF)
Last: | $0.01 |
---|---|
Change Percent: | 0.0% |
Open: | $0.01 |
Close: | $0.01 |
High: | $0.01 |
Low: | $0.01 |
Volume: | 204 |
Last Trade Date Time: | 03/04/2024 03:00:00 am |
News | Neurovive Pharm Ab Ord (OTCMKTS:NEVPF)
NeuroVive Pharmaceutical AB ( OTCQX:NEVPF ): Q4 GAAP EPS of -SEK0.15. More news on: NeuroVive Pharmaceutical AB, Neurovive Pharmaceutical AB ADR, Earnings news and commentary, Healthcare stocks news, , Read more ...
STOCKHOLM , Feb. 19, 2020 /PRNewswire/ -- Important events in 2019 KL1333 NeuroVive enrolls first subject in its European KL1333 phase Ia/b clinical study &...
Message Board Posts | Neurovive Pharm Ab Ord (OTCMKTS:NEVPF)
Subject | By | Source | When |
---|---|---|---|
Hi. I was wandering if you were invested | Chrisny73 | investorshub | 05/19/2021 5:08:32 PM |
NeuroVive Pharmaceutical AB changed to Abliva AB | Renee | investorshub | 05/29/2020 1:06:19 AM |
Just might be...thanks for the alert Chrisny73... GL...$NEVPF | Golden Cross | investorshub | 02/19/2020 7:02:34 PM |
Looks like a buying opportunity here | Chrisny73 | investorshub | 02/19/2020 6:25:00 PM |
$NEVPF Tier_Change: OTCQX International to Pink Current | Golden Cross | investorshub | 01/02/2020 7:36:10 AM |
News, Short Squeeze, Breakout and More Instantly...
Neurovive Pharm Ab Ord Company Name:
NEVPF Stock Symbol:
OTCMKTS Market:
STOCKHOLM , Feb. 19, 2020 /PRNewswire/ -- Important events in 2019 KL1333 NeuroVive enrolls first subject in its European KL1333 phase Ia/b clinical study &...
LUND, Sweden , Dec. 16, 2019 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) announced today that it has fully and finally settled the dispute with CicloMulsion AG regarding certain pharmaceutical technology. In 2004, NeuroVive entered into a License A...
- Continued Progress in KL1333 STOCKHOLM , Nov. 20, 2019 /PRNewswire/ -- Important events July - September NeuroVive initiates second part of its ongoing KL1333 Phase Ia/b clinical study NeuroSTAT receives Fast Track designation from the US Food and Drug Administration. ...